CDKN1A promotes paclitaxel resistance through mediating formation of polyploid giant cancer cells and enhancing neosis in non-small cell lung cancer [0.03%]
CDKN1A通过介导多倍体巨癌细胞的形成和增强非小细胞肺癌中的新生学来促进紫杉醇耐药性
Pan Sun,Zhenyu Huang,Yanjie Ji et al.
Pan Sun et al.
Background: Chemotherapy resistance caused by paclitaxel (PTX) is a thorny issue in the treatment of non-small cell lung cancer (NSCLC). In recent years, it has been reported that PTX can induce the formation of polyploid...
ZNF528 as a novel driver of metastasis in lung cancer: insights from single-cell transcriptomics [0.03%]
锌指蛋白528(ZNF528)在肺癌转移中的促癌功能及单细胞转录组学机制研究
Huiying Li,Yongjuan Lin,Yue Wang et al.
Huiying Li et al.
Background: Non-small cell lung cancer (NSCLC) remains a leading cause of cancer mortality due to frequent metastasis, despite therapeutic advances. This study aims to identify novel drivers of NSCLC metastasis to facilit...
The role of tumor metabolic reprogramming in acquired anti-PD-1/PD-L1 resistance [0.03%]
获得性抗PD-1 / PD-L1耐药的肿瘤代谢重编程的作用
Cize Gao,Jianing Chen,Boyue Pang et al.
Cize Gao et al.
Tumor metabolic reprogramming is a pivotal mechanism driving acquired resistance to programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) blockade therapy. Under therapeutic pressure, tumor cells undergo extensive metabol...
Neoadjuvant chemo-immunotherapy in a kidney transplant recipient with locally advanced non-small cell lung cancer: a case report of a therapeutic dilemma [0.03%]
肾移植受者局部晚期非小细胞肺癌新辅助化疗免疫治疗个案报道及治疗困境思考
Joffroy Rogier,Lucie Charon,Anne Durlach et al.
Joffroy Rogier et al.
Background: Immune checkpoint inhibitors (ICIs) have significantly improved outcomes in locally advanced non-small cell lung cancer (NSCLC), establishing chemo-ICI as the current standard of care. However, solid organ tra...
Comparative analysis of lung cancer risk factors between never-smokers and heavy smokers: a nationwide population-based study in Korea [0.03%]
基于韩国全国人群的肺癌症危险因素对比研究——从不吸烟者与重度吸烟者的比较分析
Chiwook Chung,Kyu Na Lee,Dong Wook Shin et al.
Chiwook Chung et al.
Background: Tobacco smoking is a major risk factor for lung cancer; however, more than one-third of newly diagnosed lung cancer cases in Korea occur in never-smokers. Among heavy smokers, the specific characteristics cont...
Duration of systemic therapy in patients with metastatic EGFR-mutated non-small cell lung cancer and brain metastases [0.03%]
EGFR突变型伴脑转移的晚期非小细胞肺癌患者的系统治疗持续时间
Michael Yan,Michael Tjong,Natalie Coburn et al.
Michael Yan et al.
Background: Osimertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, has demonstrated strong central nervous system (CNS) activity in EGFR-mutated metastatic non-small cell lung cancer (mNSCLC). ...
Case report: durable response to osimertinib, radiotherapy, and chemotherapy combination in advanced non-small cell lung cancer with atypical metastasis [0.03%]
病例报告：奥希替尼、放疗和化疗联合治疗罕见转移的晚期非小细胞肺癌取得长期疗效
Javier Arias-Romero,Isa Mambetsariev,Jeremy Fricke et al.
Javier Arias-Romero et al.
Background: A 71-year-old female never-smoker, with a remote history of secondhand smoke and a medical history including hyperlipidemia, hypertension, fatty liver, and chronic thrombocytopenia. Additionally, her family hi...
Advances in translational lung cancer research in 2025: a narrative review [0.03%]
2025年肺癌转化研究进展：叙事综述
Yuhan Xu,Yanbin Kuang,Yeqin Guo et al.
Yuhan Xu et al.
Background and objective: By 2025, lung cancer translational research increasingly focuses on early detection, more precise stratification, and dynamic treatment selection. Against the backdrop of drug resistance and hete...
Application of organoid models in basic and translational research of lung cancer: a narrative review [0.03%]
类器官模型在肺癌基础和转化研究中的应用：回顾式述评
Yulong Jin,Hui Li,Chenchen Tang et al.
Yulong Jin et al.
Background and objective: Lung cancer remains the leading cause of cancer-related mortality worldwide. Despite advances in targeted and immunotherapy, challenges such as drug resistance persist. Traditional experimental m...
Major histocompatibility complex II serves as a prognostic biomarker in resectable pulmonary sarcomatoid carcinoma: development of a prediction model [0.03%]
人白细胞抗原II可作为可手术肺肉瘤样癌预后生物标志物：预测模型的建立
Hao Wang,Li Ye,Xinyue Liu et al.
Hao Wang et al.
Background: Pulmonary sarcomatoid carcinoma (PSC) is a rare pulmonary malignancy, exhibiting a poor outcome even after complete resection. Major histocompatibility complex II (MHC-II) is a critical molecule in priming ant...